MAIA stock news · MAIA Biotechnology, Inc.
Get alerts for MAIA
Follow MAIA Biotechnology, Inc. (MAIA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MAIAFree on the App Store and Google Play, or on the web.
MAIA Biotechnology shared promising results from its Phase 2 study on a new lung cancer treatment.
Good for MAIAMAIA reported an 88% disease control rate in its expanded Phase 2 THIO-101 study. Results matching earlier parts favor MAIA, though the study is ongoing.
MAIA Biotechnology, Inc. shares new information about its business plans.
NeutralMAIA posted a presentation and summary, but this filing gives no new trial or sales results. It does not change the company's outlook.